NASDAQ

Airsculpt Technologies, Inc.

AIRS

5 stories

$130M Market cap · 2026-10-07

@BlueDuckCap Sep 16

BDC on X

$AIRS needs to refi their debt. Its a mega catalyst which we have no reason to believe won't happen. "term sheets on our desk". Been a frustrating stock and mgmt still has a lot to prove. Think they are the right team, but again, show me. GLP1 creating all sorts of new aesthetic demand. ASPS flagged lift/contour as the defining category. Facial fat grafting +39%, brow lift +29%, upper body lift +22%, arm lift +21%, neck lift +21%, thigh lift +20%, facelift +13%, breast lift +8% — broadest gains in the report, tied to post-GLP-1 skin laxity. AIRS has direct shots on goal to address much of this (not all). They also have partnered on AlloClae which looks timely. Checks here are encouraging. Minimally invasive still dominant by volume. Neuromodulators (~50%) and HA fillers (~30%) account for most non-surgical treatment volume — the space AIRS's new AlloClae partnership targets. These new pockets of growth need to offset what was a -1% lipo print in 2025 per ASPS. Still #1 by volume, though. Time to make it happen, Yogi. The opportunity is too big and timely for it to not start showing up. Start by signing those term sheets.

@BlueDuckCap Sep 4

BDC on X

Haven't posted $AIRS thoughts since the Q2 miss. But after speaking to management and refreshing on the thesis here's an update: 1. The opportunity for post GLP1 procedures remains as large as ever. When a new "thing" starts trending, a business such as theirs with surgeons, devices, and rigid medical process can't just turn on a dime to capture the growing opportunity in a few months. It takes a little time and the management team is measured, disciplined, and thoughtful about the best way to pivot. Why? Because this is a health care setting where you don't just throw stuff at the wall. But... 2. ...Measurable evidence of the new are opportunities (skin removal, tightening etc) gaining momentum is emerging: Skin excisions grew 100% from Q4 and have increased within the mix going from Q4 4.3%, Q1 4.9% to Q2 5.9%. That's real evidence of progress on addressing a massive post GlP1 demand wave. 3. The announced partnership with Alloclae might be a GAME CHANGER as the fat transfer procedure is hitting the zeitgeist as we speak. Alix Earle has 14mn social media followers and the rumor mill consensus is that she just had the procedure done. Sure looks like it to me. 4. I was expecting them to announce a debt refi that didn't come. Disappointing, yes. But, I still believe it is coming and management said so too: "We recently signed an amendment exceeding the maturity of the facility to November 2027. At the same time, we continue to make progress refinancing. The continued stability in our business has allowed us to receive multiple-term sheets that we believe are aligned with our long-term interest and the maturity extension gives us additional time to achieve the right transaction." 5. Mgmt keeps talking about restarting store growth given low saturation and lack of presence in many notable markets such as Long Island, Tampa, etc. You don't wave new store growth in front of the market unless you think you are going to refi the debt and have some stuff cooking to reignite SSS. Maybe more promotional management teams would, but having gotten to know this team well, I am confident that they are not inclined to promote things that they don't have high confidence in. When Yogi became CEO he literally told me no plans to go on the road and meet with investors because they need stability first. Now its a total 180 on that point. 6. There's so much operating leverage here. If the new GLP1 related opportunities continue to gain momentum, and if they add 3 stores to the 31 store base, then we grow ebitda 41% next year. Today we are trading at just 4.9x past peak adj ebitda. In five years, why can't they expand to 40 stores? Based on the unit economics per store, they would then be in position to exceed prior peak earnings. This was a mismanaged business that got hurt by the early rapid onset of GLP1, but we now know that the other side of that demand wave comes with a whole new set of demand for aesthetic work. The opportunity is absolutely massive. And if this current team doesn't get it done, then given the long term filers in the name (PE, activists), I suspect that new owners would be happy to enter the picture. Meanwhile, the short interest remains high and the top five holders aren't going anywhere. *This is not advice, just our opinion. We are long AIRS but that can change at anytime.

AIRS · long

Airsculpt Technolo INC

AirSculpt (AIRS) operates roughly 30 centers offering premium self-pay body contouring, fat removal, fat transfer and skin-tightening…

AIRS $130M

Value Investors Club May 26 1 click

@ActAccordingly Aug 13

PAA Research on X

Many. High level, the $AIRS quarter wasn't as good as hoped, but certainly not something that warranted the kind of response it received. Top of the funnel interest in lipo slowed in June/July. I have my own thesis on the potential impact of the world cup, given the shift in consumer interest in that procedure towards the latina community over the past 15-years. Only time will tell if that's right. Either way, the business is stable and now oriented for growth. Adding new procedures (eye bleph and alloclae) significantly expands $AIRS ability to serve the GLP-1 crowd. My expectation is we'll see the bank deal completed before they report 3Q26 and that could coincide with the announcement of site expansion in early 2027. The growth opportunity here remains monumental. $AIRS has massive inherent operating leverage to improved site level utilization. There was some fast money and retail involved here (clearly!), but this is about the company improving the marketing funnel in absolute lead generation and conversion, driving site level utilization, and expanding on a de novo basis. That's the recipe and obsessing about whether growth should have been 2-4% higher for 2Q26 in that context is irrelevant. This is a business that can be 3-5x the size and still have a runway for growth.

@ActAccordingly Aug 10

PAA Research on X

I still own $AIRS and think it will work. The company is in a much better financial and operational position than it was a year ago. Heading into the quarter, I thought they would post 3-5% same center comps, instead we got a 1% and they stated June/July was "soft". Guidance came down $1.0-$1.5MM for EBITDA, probably not the stuff (-40%+) declines are made of, but you have a ton of fast money and retail here. Brutal. However, the company spent a fair amount on top of the funnel brand marketing the past 3-6 months, the returns on that spend are longer tail in nature. Leverage is <2.0x now. They keep adding to the "menu" for procedures, which should drive significant improvements in site utilization and incremental margins that could approach 40-50%. This business has the potential to reach 150-200 units at 20-25% EBITDA margins. That would represent $1.0B in topline and $200MM+ of EBITDA. Obviously that doesn't happen anytime soon, but they can get back to de novo site expansion of 2-4 units a year starting in 2027 to get the growth flywheel going. The industry remains incredibly fragmented and the GLP-1 tailwinds for aesthetics are quite real. It's kind of remarkable the stock trades like this given the size of the float, which is probably only 12-13MM shares. Hopefully we'll see some insider buying in the coming days. At these levels, this would be an attractive asset for quite a few potential buyers IMO.